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Our experimental design has been divided into three parts: (1) an acute study involving the administration of single doses of the drugs to normal subjects, (2) a six-day study in normal subjects, and (3) a seven-day balance study in hypertensive patients.
Short-term study
Methods. The study was carried out in 8 healthy young male volunteers who were admitted to the hospital for 36 hours. Prior to admission, they were given a "no added salt diet" and received supplementary sodium chloride (3 Gm. per day) with a mean sodium intake of 180 mEq. per day. After midnight of the day of the experiment, no food or fluid intake was allowed; but during the next day, a standard sodium intake of 110 mEq. and a fluid intake of 200 ml. every 2 hours was given over a 14 hour period. No coffee, tea, or alcohol was given. At 8:00 A.M. the subjects received unidentified capsules of MK, He, a combination of both, or a placebo. The order in which the subjects were given the drugs was determined by the Latin square method.
ject remained on the prescribed diet for one week. The subjects voided at 8:00 A.M. and thereafter every 2 hours for 16 hours and an overnight specimen from the sixteenth to twenty-fourth hours. Sodium, potassium, chloride, pH, bicarbonate, titrable acidity, osmolality, and creatinine levels were determined in each urine sample. Uric acid output was deBetween each of these studies, the sub- termined for the whole 24 hour period. A single venous blood sample was drawn without venous stasis at 8:00 A.M. for sodium, potassium, chloride, bicarbonate, osmolality, and creatinine determinations. Sodium and potassium were determined by flame photometry. Automated colorimetric methods were used for creatinine, chloride, and uric acid analyses. Osmolal concentrations were determined by the freezing point technique with the use of a Fiske osmometer. Titratable acid in urine was determined by titrating a small aliquot to pH 7.4 with 0.10N base, with a pH meter. Carbon dioxide content was measured on carefully protected urine and serum specimens with a Natelson microgasometer. These methods apply to all the parts of this report.
Two dosage levels of the drugs have been studied. Four subjects received 10 mg. MK (approximately 0.15 mg. per kilogram), 50 mg. HC, or two placebo capsules. The other 4 subjects received the same medications at double the above doses.
Results. Fig. 1 illustrates the time course and total effect of each drug regimen at the lower dosage as compared with placebo. In the doses given, MK had a slightly slower onset of action and both the peak natriuretic response and total effect were lower than for He. The combination of the two drugs increased the output of sodium in 24 hours from 361 to When the higher dose of the drug was used, the output of sodium was not significantly greater with HC; with MK, the output of sodium increased by only 53 mEq. per 24 hours and this carried over to the combination of drugs (Table I ). The potassium-conserving effect of MK was more prominent at the higher dosage and this was maintained when the drugs were given together.
Six day study in normal subjects
Methods. This study was performed on an outpatient basis in 8 male subjects. Twenty-four hour urine collections were taken and measured for 4 days prior to treatment and for 6 days during treatment with MK. The volunteers ate a normal diet; only the intake of foods with high purine content was prohibited (liver, kidney). Tea and coffee were permitted, but in those who did it was mandatory that they take either two cups of coffee or tea per day. The subjects received MK, 5 mg. twice a day for 4 days, and then MK, 10 mg. twice a day for the remaining 2 days. A blood sample was drawn on three occasions before treatment and after the first, second, and fifth day of treatment for determination of sodium, potassium, chloride, HC0 3 , creatinine, uric acid, and hematocrit. In the urine, determinations of sodium, potassium, chloride, creatinine, and uric acid were made.
Three of these subjects undertook a further trial with MK at 30 mg. per day in divided dosage for 3 days to determine the blood levels of the drug. \) Venous blood samples were drawn, four after the first 10 mg. dose and then daily for 3 days.
~Determination of blood levels were performed for us by Merck Sharp & Dohme through the courtesy of Dr. P. W. Boyles. Results. The results of this study are presented in Table II . There was a modest increase in sodium output; the potassium excretion showed a slight drop for 3 days and returned to control levels on the fourth day. The increased dosage at this point had a small but temporary effect on the potassium output. The average uric acid level in the serum was 6.13 mg. per cent prior to the treatment and 6.04 mg. per cent after 5 days of treatment. Uric acid clearance did not change. There was a small drop in serum HC0 3 , with no substantial change in serum sodium, potassium" or chloride. There was no significant change in serum creatinine Or in its excretion in the urine. A transient increase of the mean hematocrit level occurred after 2 days of treatment from 46 to 48 per cent.
Uric acid
The blood levels of MK increased from undectable levels to 0.02 mg. per milliliter within 4 hours of the administration of the first dose and then varied between 0.02 to 0.04 mg. per milliliter for the succeeding 3 days without evidence of progressive increase.
Balance study in hypertensive patients
Methods. These studies were carried out in the Clinical Research Unit of the University of Michigan Hospital on 15 untreated hypertensive patients. These patients were recruited from the outpatient clinic, and their disease states were of moderate severity with a mean blood pres- sure of 169/107 mm. Hg. None had papilledema or hemorrhages and exudates. The subjects had normal renal function and no evidence of cardiac failure; clinical edema was not evident in any subject. They were given a 44 mEq. sodium diet with supplementation to 94.8 mEq. per day. There was no fluid restriction. Body weight was recorded daily and a determination was made of serum sodium, potassium, chloride, bicarbonate, uric acid, and creatinine. The urine was collected every 24 hours for determination of vohune, sodium, potassium, chloride, creatinine, and uric acid. After a control period of 4 days, the 15 subjects were divided into 3 groups of 5 each. Group A was treated with MK, 30 mg. per day for 5 days, which was then discontinued and immediately changed to He, 100 mg. per day for 2 days. In Group B, the effect of He, 100 mg. per day, was studied. After 5 days MK, 30 mg. per day was added. In Group e, 50 mg. per day of He was given, and after 5 days 30 mg. per day of MK was added.
Results.
Group A. The results of Group A are shown in Table III . A rise in urine volume was observed and maintained for the 5 days of treatment with MK. The body weight showed a moderate but steady decrease of 1.4 Kg. and decreased further with the addition of He. The sodium output increased with MK, being greatest on the :6rst day of the drug administration (162.8 mEq. per day) and falling to 107.0 mEq. per day in 5 days. The change to He treatment at this point increased the output to 132.8 mEq. per day, demonstrating He to be a more potent diuretic in the dosage used.
The creatinine clearance was reduced by 14.4 L. per day with administration of MK and was further reduced with He. A Table IV . When compared with the response to MK, the sodium excretion was initially much greater with He. On the first day of treatment it reached a peak of 267.8 mEq. per day but it fell rapidly to 70 mEq. per day in 5 days; it rose when MK was added. Simultaneously, there was a fall in serum sodium concentration from 141.2 to 138.2 mEq. with He and to 137.5 with the combination. The total negative sodium balance at this point was calculated to be 302.7 mEq. The potassium excretion increased markedly with He and was sustained over the 5 day period of treatment, with a fall in the serum value from 4.1 ± 0.35 to 3.35 ± 0.06. With the addition of MK, potassium excretion was greatly reduced and the serum value returned to 4.38 ± 0.17 in 2 days.
The mean blood pressure in this section of the study fell from 172/110 to 150/94 with He and to 134/90 mm. Hg with the combination treatment of the two diuretics.
While He was initially more potent than MK, its action was not sustained. When the 5 day periods during which each drug was given alone are compared, the total negative sodium balance with MK was 222.0 mEq. and 188.0 mEq. with He. Since the patterns of response to MK and He were so different, it seemed desirable to determine whether this was a reflection of different pharmacologic properties of the two drugs or whether this was the result of differences in potency. A further trial was therefore, made with He at lower dosage.
Results
Group C. With reduced dosage of He (50 mg. per day), the peak response on the Rrst day (240.0 mEq.) was a little lower than that achieved with the higher dose (Table V) . On succeeding days, the response fell off sharply and on the third day was below the intake level (85.4 mEq. per day). On the Rfth day, the sodium balance was markedly positive; at this point the addition of MK (30 mg. per day) greatly increased sodium output.
Discussion
The sodium excretion with MK administration, in the doses used, when given as a single dose or for a single day never reached the peak values achieved by He. However, when the drug was given on successive days, the effectiveness of MK was better sustained; and over a 5 day period, the negative balance achieved was approXimately the same as that with He at the conventional maximal dosage of 100 mg. per day. There are several possible explanations for this. If there were a given quantity of sodium which could be readily removed, the weaker drug might continue to be effective until this was accomplished. This is not supported by the observations with He, in which reduction in dosage did not prolong response but shortened it.
Tissue levels of MK might increase on successive days. Others have found some evidence in 3 subjects for increasing blood concentration of MK, which could not be confirmed by us. MK may possess a dual action-a direct natriuretic effect and another and different one sustaining the natriuretic effect. This possibility is of interest since a response sustained over many days has also been observed with spironolactone. 7 Thus, the continued availability of both potassium and chloride ions at the tubular exchange sites may assist the continued sodium output. Another possibility for the prolonged natriuretic effect is the production of a mild acidosis. This along with potassium retention will favor the movement of sodium from muscle cells into the extracellular fluid and make it available for excretion. 3 It would be expected, therefore, that MK would result in an extraction of sodium from both the cellular and extracellular compartment, whereas He would tend to bring about a loss of sodium from extracellular fluid with the possible accumulation of sodium in muscle cells.
He and MK are for practical purposes, therefore, approximately equal in potency and in combination produce additive diuresis. Since it has been our feeling that the small size of the negative sodium balance achieved by He limits its antihypertensive action, 2 this combination may be of value in the treatment of hypertension. Furthermore, the added diuretic response may well be achieved without hypokalemia or alkalosis since the potassium retention achieved by MK can balance the loss from He.
The potassium-saving effect was to be expected, from evidence in other studies. 1 , 6, 8, 9 This effect is similar to that of triamterene 5 ; but there is a less pronounced bicarbonate excretion and, therefore, a metabolic acidosis seems to occur more readily with MK than with triamterene. Thus, the effect of MK counteracting the metabolic hypokalemic alkalosis produced by He seems to be more effective than that of triamterene. Since the single-dose studies showed that potassium output fell below control and in the longer studies serum potassium rose, it is misleading to use the term "potassium-sparing." Actually, there is potassium retention and hyperkalemia could occur. The accumulation of potassium in the doses used in this study appears to be limited to 2 to 3 days, however, and even when the drug is given on successive days, the output returns to control levels.
The decrease of the creatinine clearance which takes place with MK is similar to that with He. This is not surprising since reduced renal blood flow and glomerular filtration rate have been reported with both ethacrynic acid and hydrochlorothiazide. 4 This appears to be a response to the contraction in extracellular fluid volume and not the result of a specific effect of these drugs, since it is evident only after a considerable loss of sodium.
The effect of MK on uric acid excretion requires further study; it seems that a mild uricosuric action may have occurred after single doses as well as after a five day treatment. This could not, however, be demonstrated on a daily dose of 10 to 20 mg, MK over several days in outpatients.
At first glance MK seemed to be a mild diuretic with the virtue of conserving potassium. However, when given repeatedly over several days, its effect was better maintained than that of He. The negative sodium balance achieved is the same with both agents. When combined, a substantial natriuretic effect could be induced without hypokalemia. MK appeared to possess antihypertensive properties, as do other diuretic agents, and the combination with He appeared to increase it. Since the effect of bed rest in these studies complicates the estimation of the antihypertensive effect, a different experimental design
